What changed in West Pharmaceutical Services, Inc.'s latest annual report
In the year ended 31 Dec 2025, West Pharmaceutical Services, Inc.'s revenue rose 6.3% to USD 3.07bn, from USD 2.89bn; net income rose 0.2% to USD 493.70m, from USD 492.70m; cash and cash equivalents rose 63.3% to USD 791.30m, from USD 484.60m.
Year ended 31 Dec 2025. Source: 10-K filed 17 Feb 2026, read it on SEC EDGAR.
USD 2.89bn to USD 3.07bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 2.89bn | 3.07bn | Up 6.3% |
| Net income | 492.70m | 493.70m | Up 0.2% |
| Total assets | 3.64bn | 4.27bn | Up 17.2% |
| Total liabilities | 961.10m | 1.09bn | Up 13.8% |
| Long-term debt | 202.60m | 202.80m | Up 0.1% |
| Cash and cash equivalents | 484.60m | 791.30m | Up 63.3% |
| Shareholders' equity | 2.68bn | 3.18bn | Up 18.4% |
Questions people ask
Did West Pharmaceutical Services, Inc.'s revenue grow last year?
Revenue grew 6.3%, from USD 2.89bn to USD 3.07bn in the year ended 31 Dec 2025.
Is West Pharmaceutical Services, Inc. profitable?
Yes. Net income was USD 493.70m in the year ended 31 Dec 2025. The year before: USD 492.70m.
How much cash and debt does West Pharmaceutical Services, Inc. have?
At its latest year end (31 Dec 2025), West Pharmaceutical Services, Inc. reported cash and cash equivalents of USD 791.30m and long-term debt of USD 202.80m.
Where do these numbers come from?
From West Pharmaceutical Services, Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with West Pharmaceutical Services, Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Surgical & Medical Instruments & Apparatus companies
- Stryker CorpLong-term debt up 21.9%
- 3M CompanyShareholders' equity up 22.4%
- Boston Scientific CorporationCash and cash equivalents up 374.6%
- Becton, Dickinson And CompanyCash and cash equivalents down 62.7%
- Medline Inc.Cash and cash equivalents up 874.4%
- ResMed Inc.Long-term debt down 39.3%
- Dexcom, Inc.Cash and cash equivalents up 51.4%
- Solventum CorporationNet income up 224.8%